For research and educational use. PepCaddie does not sell peptides and recommends no doses.
PepCaddie
Build
Plain reference

Glow Blend guide

PepCaddiePublished

PepCaddie provides educational summaries of published and registered research. It does not sell peptides, provide medical advice, or recommend the use of any investigational substance. Discuss health decisions with a qualified healthcare professional.

Glow Blend is three peptides in one vial: BPC-157, TB-500 and GHK-Cu. No study of that combination exists, in any species13. What does exist is one animal experiment that tested two of the three together, and it found that combining them added nothing1.

The short answer

  • Studies of this blend: none13.
  • Closest thing: a rat study of two components, where the combination was no better than either alone1.
  • The components are not comparable: one has controlled human trials, one has no completed trial, one has never been given to a human54.
  • Regulatory status: all three sit on the same FDA withdrawn-nomination list, none permitted for compounding267.
  • In sport: two of the three are named on the prohibited list8.

The one experiment that tested part of this blend

In 2026 a group repaired the Achilles tendons of 32 rats and split them four ways: nothing, BPC-157 alone, TB-500 alone, and both together. It is the closest anyone has come to testing a blend.

On tendon strength, only TB-500 alone reached significance against controls. On tissue structure, TB-500 and the combination both improved and BPC-157 alone did not reach significance. And then the sentence that matters if you are buying a blend, in the authors' own words: combined treatment did not confer additional benefits compared to either agent alone1.

Their suggested explanation is worth understanding, because it generalises. The two peptides may converge on the same downstream pathway — in which case adding the second one to the first buys you nothing, no matter how good each looks separately. They flag this as a hypothesis needing confirmation. It is eight rats per group over four weeks, and its authors call it exploratory.

The real problem: these three are not comparable

A blend invites you to think of its components as three versions of the same thing. They are not, and the gap between them is the most useful fact on this page.

GHK-Cu has controlled human trials. They are topical, they are more than thirty years old, and they disagree with each other: in venous leg ulcers a copper tripeptide cream did not separate from an inert vehicle, while a trial in diabetic foot ulcers reported a large benefit5. Uneven evidence, but real human evidence.

BPC-157 has no completed controlled human efficacy trial at all.

TB-500 is the starkest. FDA states it found no published article in which TB-500 was administered to a human, and that TB-500 is not the same substance as thymosin beta-4, despite websites using the names interchangeably54. Every trial cited for it studied a different molecule.

So a product combining all three inherits one component's mixed topical evidence, one component's absence of trials, and one component's absence of any human exposure whatsoever — and presents the result as a single thing.

What a shared vial adds

All three components appear on the same FDA list: substances nominated for compounding and then withdrawn by their nominators. None is on the list pharmacies may compound with267. The concern FDA states for them is an immune reaction caused by peptides clumping together, or by the impurities sitting alongside them in the vial2.

FDA also found these substances poorly characterised chemically, with impurity, aggregate and endotoxin data missing from the published record34. Every one of those reviews examined one substance at a time. Nobody has looked at what three of them do to each other in a shared solution.

That is not a rhetorical point. There is no published study of whether these peptides stay stable when mixed, whether they interfere with one another, or what happens to them after injection as a mixture[unverified]. The absence is recorded here rather than filled in with speculation.

The market around it

A 2026 clinical review of the unregulated injectable peptide market names BPC-157 and TB-500 among substances lacking established human safety profiles, and lists the risks it considers relevant: product contamination, manufacturing impurities and inaccurate dosing6. Those are mechanisms of concern rather than harms measured in users, and they apply to the supply chain rather than to the molecules.

For anyone subject to drug testing: BPC-157 is named on the 2026 prohibited list among substances no health authority has approved, and thymosin beta-4 and its derivatives are named in the growth factor section with TB-500 given as the example. Both are banned at all times, in and out of competition. GHK-Cu is not named — which is not the same as permitted8.

Read the components instead

Everything actually known about this product is known about its parts, and each has its own fully sourced page here. That is where the evidence is, and a blend page cannot improve on it.

Where the rest of the detail lives

The interactive library on the homepage carries the fuller reference entry for Glow Blend, including the amounts and handling notes it holds for every compound. That is general reference information, the same for every visitor.

Open the full Glow Blend reference in the library

References

These are the sources behind this page, listed so you can read them yourself rather than take our word for it. Animal and laboratory findings do not establish that something works or is safe in people. Doses and protocols shown on a study card are that study's research parameters, not recommendations. PepCaddie does not sell peptides and does not choose a dose for anyone; this is educational material and it does not replace a qualified healthcare professional.

  • The only test of two of these components together

    2026

    Animal studyNot human evidence

    RatsBPC-157 10 µg/kg/day and TB-500 60 µg/kg/day studied4 weeksTendon strength and structure

    The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.

    This is the closest thing to a test of a blend that exists anywhere. Repaired rat Achilles tendons were treated with BPC-157 alone, TB-500 alone, both together, or nothing. On strength, only TB-500 reached significance against controls. On tissue structure, TB-500 and the combination both improved, and BPC-157 alone did not reach significance. The sentence that matters for anyone buying a blend is the authors’ own: combined treatment did not confer additional benefits compared to either agent alone.

    Limitation: Eight rats per group over four weeks, described by its authors as exploratory, and it tests two of the three components rather than the blend. The authors suggest the lack of an additive effect may mean the two peptides converge on the same pathway, and say that idea needs confirming.

    Four-arm controlled animal study: control, each peptide alone, and both combinedView study: The only test of two of these components together

  • The one component with controlled human trials

    1992

    Human randomised trial

    Adults with venous stasis ulcers0.4% cream studiedUlcer size

    The dose above is the amount used in this study. It is research information, not a recommended dose, and PepCaddie does not convert study doses into human doses.

    GHK-Cu is the only component of this blend with controlled human trials behind it, and they disagree with each other. In this one, a copper tripeptide cream did not separate from an inert vehicle in venous leg ulcers, while silver sulfadiazine did. A separate trial in diabetic foot ulcers reported a large benefit. Both are topical, and both are more than thirty years old.

    Limitation: This is evidence about GHK-Cu applied to a wound as a cream, not about GHK-Cu injected, and certainly not about it mixed with two other peptides.

    Randomised, evaluator-blinded, three-arm trial against an inert vehicleView study: The one component with controlled human trials

  • A 2026 review of the injectable peptide market

    2026

    Narrative review

    HumansReported risks

    A clinical review of the unregulated injectable peptide market that names BPC-157, TB-500 and melanotan II among substances lacking established human safety profiles. It lists the risks it considers relevant: product contamination, manufacturing impurities, inaccurate dosing, unwanted blood vessel growth, cancer risk and cardiovascular stress.

    Limitation: A narrative review written to alert clinicians, not a study. The risks it names are mechanisms of concern rather than harms measured in users of these products.

    Narrative reviewView study: A 2026 review of the injectable peptide market

Keep reading